-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports by Yimaike★Innovative immunotherapy has achieved another breakthrough! AI-driven personalized cancer vaccine announces positive data from phase I studyYimai Meng broke the news ★Baidu and Sanofi have joined forces! Innovative algorithm empowers mRNA developmentMedClub broke the news November 25, 2021/eMedClub News/--EpicentRx, a clinical-stage biotechnology company focusing on the development of oncolytic viruses and cancer small molecule therapies, recently announced that it has obtained a US patent The patent is issued by the Trademark Office (USPTO), the patent name is "Immunomodulatory Fusion Proteins", and the US patent number is 10,906,957
.
The patent refers to EpicentRx's new therapeutic protein-TGF-ß capture fusion protein (TGF-ß Trap), including the use of TGF-ß Trap alone and in combination with viral expression/delivery vectors
.
The patent will strengthen EpcentRx's intellectual property status and the coverage of its main oncolytic virus candidate therapy AdAPT-001
.
AdAPT-001 is an improved replicating type 5 adenovirus developed by EpicentRx based on its AdAPT™ immunotherapy platform
.
AdAPT-001 encodes TGF-β Trap, which aims to selectively replicate and kill tumor cells in tumor cells
.
AdAPT-001 is currently being evaluated in phase 1 clinical trials for solid tumors
.
TGF-ß Trap is designed to neutralize the signaling molecule TGF-ß, which is overproduced in many disease states, including cancers where TGF-ß drives immunosuppression
.
TGF-ß is also cirrhosis, Crohn’s disease, scleroderma, arteriosclerosis, non-alcoholic steatohepatitis (NASH), diabetic nephropathy, idiopathic pulmonary fibrosis, chronic graft versus host disease, keloid formation, etc.
One of the main drivers of fibrotic diseases
.
EpcentRx CEO Tony R.
Reid, MD, said: "This patent expands the scope of our oncolytic adenovirus intellectual property rights
.
In addition, in many diseases, TGF-β induces fibrosis and cancer cell immunity.
The key driver of escape
.
For these diseases, TGF-ß Trap protein can also be used as an independent therapeutic agent
.
"Improve targeting and weaken immune escape.
AdAPT platform immunotherapy can produce controllable infections in tumors and induce innate immunity.
The response and adaptive immune response will “warm” the “cold” tumor to treat the disease and prevent recurrence
.
▲ Picture source: The tumor expression of EpcentRx transforming growth factor β (TGFβ) is a key factor of immunosuppression
.
Tumor cells suppress the immune response through mechanisms such as TGFβ protein, thereby evading efficient T cell killing
.
AdAPT-001 oncolytic virus therapy not only infects cancer cells, it also produces TGFβ "trap" molecules (TGF-ß Trap) to neutralize TGFβ in the tumor, eliminate the tumor defense mechanism in the body, and keep the immune system activated To fight cancer
.
In addition to AdAPT-001, there is also a "personalized" oncolytic virus product AdAPT-PSV developed on the same platform in the EpcentRx pipeline, which has also entered the phase 1 clinical stage
.
AdAPT-PSV "arms" the neoantigens or peptide fragments from each patient's tumor.
These neoantigens are determined using the genetic sequencing of the patient's cancer
.
AdAPT-PSV can specifically target cancer cells and replicate in cancer cells, while amplifying neoantigen signals to activate the immune system to target cancer
.
AdAPT-001 and AdAPT-PSV are two oncolytic virus therapies that are administered by intratumoral injection, but EpcentRx is also working closely with the University of California San Diego Research Center to develop the use of nanoparticle encapsulation technology to achieve intravenous injection (systemic drug delivery).
) Method of delivering AdAPT virus
.
EpcentRx is committed to developing treatments suitable for all cancer patients, including tumor types that cannot be administered intratumorally
.
Oncolytic virus "arming" strategy Oncolytic viruses work through dual mechanisms: 1) selectively replicate and lyse infected cancer cells; 2) induce host anti-tumor immunity
.
In addition, the oncolytic virus can also be genetically modified to insert therapeutic genes as a vector to play a synergistic role in killing tumor cells in multiple ways, which can effectively avoid the current common drug resistance problem of single-target anti-cancer drugs
.
This step is also called "arming", just like adding an oncolytic virus with a cancer-killing "accomplice"
.
There are a variety of therapeutic exogenous genes currently under research, including: cell death-related molecules that can directly induce tumor cell death, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), tumor suppressor gene P53, etc.
; Angiogenesis molecules that inhibit tumor tissue angiogenesis, such as endostatin, vascular endothelial cell growth inhibitory factor (VEGI); immune regulatory factors, such as immune-related cytokines (GM-CSF, IL-2, interferon), chemotactic Factors (CCL5, CCL20, CCL21), other factors that can induce anti-tumor immune responses (viral membrane proteins, HSP70), etc.
; small RNA molecules (small RNA) that inhibit tumor-related genes, such as miRNA, siRNA, shRNA, and lncRNA
.
The first oncolytic virus T-VEC approved by the FDA is a type I herpes simplex virus (HSV-1) with GM-CSF armed in its genome
.
GM-CSF is a commonly used cytokine for oncolytic viruses.
Local release of GM-CSF from oncolytic viruses can promote the maturation and migration of DC cells and enhance the immune response of T cells
.
Reference materials: 1.
https:// .
https://#adaptpsv
.
The patent refers to EpicentRx's new therapeutic protein-TGF-ß capture fusion protein (TGF-ß Trap), including the use of TGF-ß Trap alone and in combination with viral expression/delivery vectors
.
The patent will strengthen EpcentRx's intellectual property status and the coverage of its main oncolytic virus candidate therapy AdAPT-001
.
AdAPT-001 is an improved replicating type 5 adenovirus developed by EpicentRx based on its AdAPT™ immunotherapy platform
.
AdAPT-001 encodes TGF-β Trap, which aims to selectively replicate and kill tumor cells in tumor cells
.
AdAPT-001 is currently being evaluated in phase 1 clinical trials for solid tumors
.
TGF-ß Trap is designed to neutralize the signaling molecule TGF-ß, which is overproduced in many disease states, including cancers where TGF-ß drives immunosuppression
.
TGF-ß is also cirrhosis, Crohn’s disease, scleroderma, arteriosclerosis, non-alcoholic steatohepatitis (NASH), diabetic nephropathy, idiopathic pulmonary fibrosis, chronic graft versus host disease, keloid formation, etc.
One of the main drivers of fibrotic diseases
.
EpcentRx CEO Tony R.
Reid, MD, said: "This patent expands the scope of our oncolytic adenovirus intellectual property rights
.
In addition, in many diseases, TGF-β induces fibrosis and cancer cell immunity.
The key driver of escape
.
For these diseases, TGF-ß Trap protein can also be used as an independent therapeutic agent
.
"Improve targeting and weaken immune escape.
AdAPT platform immunotherapy can produce controllable infections in tumors and induce innate immunity.
The response and adaptive immune response will “warm” the “cold” tumor to treat the disease and prevent recurrence
.
▲ Picture source: The tumor expression of EpcentRx transforming growth factor β (TGFβ) is a key factor of immunosuppression
.
Tumor cells suppress the immune response through mechanisms such as TGFβ protein, thereby evading efficient T cell killing
.
AdAPT-001 oncolytic virus therapy not only infects cancer cells, it also produces TGFβ "trap" molecules (TGF-ß Trap) to neutralize TGFβ in the tumor, eliminate the tumor defense mechanism in the body, and keep the immune system activated To fight cancer
.
In addition to AdAPT-001, there is also a "personalized" oncolytic virus product AdAPT-PSV developed on the same platform in the EpcentRx pipeline, which has also entered the phase 1 clinical stage
.
AdAPT-PSV "arms" the neoantigens or peptide fragments from each patient's tumor.
These neoantigens are determined using the genetic sequencing of the patient's cancer
.
AdAPT-PSV can specifically target cancer cells and replicate in cancer cells, while amplifying neoantigen signals to activate the immune system to target cancer
.
AdAPT-001 and AdAPT-PSV are two oncolytic virus therapies that are administered by intratumoral injection, but EpcentRx is also working closely with the University of California San Diego Research Center to develop the use of nanoparticle encapsulation technology to achieve intravenous injection (systemic drug delivery).
) Method of delivering AdAPT virus
.
EpcentRx is committed to developing treatments suitable for all cancer patients, including tumor types that cannot be administered intratumorally
.
Oncolytic virus "arming" strategy Oncolytic viruses work through dual mechanisms: 1) selectively replicate and lyse infected cancer cells; 2) induce host anti-tumor immunity
.
In addition, the oncolytic virus can also be genetically modified to insert therapeutic genes as a vector to play a synergistic role in killing tumor cells in multiple ways, which can effectively avoid the current common drug resistance problem of single-target anti-cancer drugs
.
This step is also called "arming", just like adding an oncolytic virus with a cancer-killing "accomplice"
.
There are a variety of therapeutic exogenous genes currently under research, including: cell death-related molecules that can directly induce tumor cell death, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), tumor suppressor gene P53, etc.
; Angiogenesis molecules that inhibit tumor tissue angiogenesis, such as endostatin, vascular endothelial cell growth inhibitory factor (VEGI); immune regulatory factors, such as immune-related cytokines (GM-CSF, IL-2, interferon), chemotactic Factors (CCL5, CCL20, CCL21), other factors that can induce anti-tumor immune responses (viral membrane proteins, HSP70), etc.
; small RNA molecules (small RNA) that inhibit tumor-related genes, such as miRNA, siRNA, shRNA, and lncRNA
.
The first oncolytic virus T-VEC approved by the FDA is a type I herpes simplex virus (HSV-1) with GM-CSF armed in its genome
.
GM-CSF is a commonly used cytokine for oncolytic viruses.
Local release of GM-CSF from oncolytic viruses can promote the maturation and migration of DC cells and enhance the immune response of T cells
.
Reference materials: 1.
https:// .
https://#adaptpsv
